The FDA has approved baricitinib in a 2 mg tablet dose to treat patients with moderate to severe active rheumatoid arthritis…
BMD Not a Reliable Predictor of Vertebral Fragility Fracture in Older Women
NEW YORK (Reuters Health)—Bone mineral density (BMD), particularly lumbar BMD, may not reliably indicate the presence of asymptomatic vertebral fragility fractures in post-menopausal women, new findings suggest. In a study online May 9 in Bone, Italian researchers found such fractures were common among women seen at an osteoporosis clinic, yet the vast majority had not…
Disease-Modifying Antirheumatic Drugs Cut RA Risk
NEW YORK (Reuters Health)—Disease-modifying antirheumatic drugs (DMARDs) reduce the risk of developing rheumatoid arthritis (RA) in patients with early undifferentiated arthritis, researchers from France report. Several studies have suggested that conventional or biological DMARDs might interfere with the pathogenic process and prevent more established forms of RA, but it remains unclear whether these drugs are…
Bringing Policy & Practice Together: A Conversation with GAC Member Ethan Craig, MD, MHS
In his clinic as a third-year fellow at Johns Hopkins Hospital in Baltimore, Ethan Craig, MD, MHS, says it’s not always easy to hear about patients struggling with step therapy or other barriers to treatment. However, as a member of the ACR’s Government Affairs Committee (GAC), he says his work to understand and improve policy…
Join Us for an Advanced Rheumatology Coding & Practice Management Summit in Chicago
Before the ACR/ARHP Annual Meeting gets started in Chicago in October, the ACR’s pre-meeting practice management and coding courses offer an intensive educational opportunity. The Oct. 19–20 sessions, ACR Coding Course: Unlock the Mysteries of Advanced Coding for Rheumatology and Practice Management: Putting the Pieces Together—Winning Strategies for Rheumatology Practices, are the industry’s premier events…
ACR’s 2018 Advocates for Arthritis & Advocacy 101 Program
On Sept. 23–25, the ACR will once again hold its annual Advocates for Arthritis fly-in event in Washington, D.C. Held in conjunction with the ACR’s Advocacy 101 course, the fly-in is a great way for members and their patients to learn about issues important to the practice of rheumatology and have the opportunity to actively…
ACR Responds to Drug Pricing Proposals
Responding to the Trump administration’s drug pricing proposals, the ACR released a set of principles it hopes will help guide any drug policy changes.1 The principles underscore what is critically needed for rheumatologists to provide the best and safest care to their patients, many of whom require ongoing treatment for chronic conditions. “The ACR has…
AMA House of Delegates 2018 Annual Meeting Recap
On June 8–13, the AMA House of Delegates (HOD) came together in Chicago for its 2018 Annual Meeting. With the recent change in apportionment of geographic and specialty delegates now equal to each other, more than 600 members of the HOD were present, with several hundred staff and attendees from the AMA and other medical…
Understanding & Preparing for Payer Audits
Audit activity among Medicare and most third-party payers has increased in response to pressure to reduce healthcare costs. The return of billions of dollars to Medicare, Medicaid and third-party programs through these medical audit reviews has also increased. For example, the Government Accountability Office (GAO) 2014 Annual Report estimated that the Centers for Medicare &…
ACR/ARHP Advocacy Leaders Lobby U.S. Congress
On May 16 and 17, ACR/ARHP leaders serving on the Board of Directors, Affiliate Society Council, Government Affairs Committee, Committee on Rheumatologic Care, RheumPAC Committee and Insurance Subcommittee once again went to Capitol Hill to advocate on behalf of ACR/ARHP members and their patients. The group represented 27 states and the District of Columbia, and…
- « Previous Page
- 1
- …
- 311
- 312
- 313
- 314
- 315
- …
- 797
- Next Page »